Efficacy of thalidomide plus MP regimen for treatment of the patients with multiple myeloma / 白血病·淋巴瘤

Objective To compare the efficacy and toxicity of melphalan + prednisone + thalidomide regimen (MPT) and melphalan + prednisone regimen (MP) in the treatment of multiple myeloma (MM).was given 100-200 mg/d everyday. 21 cases in MP group, the dose of melphalan and prednisone were the same as that in MPT group. The efficacy was evaluated after 6 cycles of treatment. Results The overall response rate (ORR) of MPT group and MP group were 65.4 % and 42.9 %, respectively (P＞O.05). The median response time in MPT group versus MP group was 2 months versus 3 months. Compared with the MP group. the increase of hemoglobin and albumin concentration in the MPT group is significantly higher (P＜ 0.05).The incidence of adverse effects of MPT group was higher than that of MP group (P ＜0.05), but the percentage of grade 3 and grade 4 toxicity was no different. The median PFS in MPT group was 11 months, 2-year PFS was 66.18 %. Conclusion Compared with MP, MPT could achieve higher response rate, improve the life quality and prolong the survival time of MM patients with better tolerance.

The rapeutic effect of Shengrong Capsule with combinations of chemotherapy in treatment of advanced non-small-cell lung cancer / 肿瘤研究与临床

Objective The observation Shengrong Capsule union chemotherapy treatment to a treatment invalid non-small-cell lung cancer curative effect and the poisonous side reaction.Methods Using Shengrong Capsule to unite other commonly used chemotherapy medicine compositions the union ehemotheraPY plan to treat the non-small-cell lung cancer 68 examples to observe its curative effect and the poisonous side effect.Results Treatment group in the near future alleviating rate 89.2%,comparison group 70.1%;Symptom improvement rate:The treatment group 81.5%,the comparison group is 53.9%;The white blood cell descending rate treatment group is 29.0%,the comparison group is 41.9%;The blood platelet descending rate treatment group is 29.0%,the comparison group is 48.4%;Statistics processing has the remarkable difference(P＜0.05).Conclusion This group of materials demonstrated Shengrong Capsule joinfly to treat the non-small cell lung cancer with other chemotherapy medicines to obtain 89.2% alleviating rate,also can the obvious blood and the non-system a sanguineum poisonous side reaction,Shengrong Capsule be is effective,economical and safe.